biostudies-literatureUnknown13Su JThree chalcone derivatives, abelmanihotols A-C <b>(1-3)</b>, and nine known compounds were isolated from <i>A. manihot</i> seeds, and their structures were determined using HRESIMS and NMR spectroscopic analysis. Compound <b>1</b> exhibited the most potent inhibitory effect (IC₅₀ = 4.79 ± 0.72 μM) against lipopolysaccharide (LPS)-induced NO release in THP-1 cells, and <b>s</b>ignificantly inhibited interleukin 1β (IL-1β) secretion, which is stimulated by LPS plus nigericin (IC₅₀ = 11.86 ± 1.20 μM), ATP or MSU, in THP-1 cells. A preliminary mechanism of action study indicated that compound <b>1</b> blocked the formation of nucleotide oligomerization domain-like receptor protein-3 (NLRP3) inflammasome formation by suppressing apoptosis-associated speck-like protein oligFrontiers in pharmacology932198https://www.ebi.ac.uk/biostudies/studies/S-EPMC9301202biostudies-literatureChalcone Derivatives From <i>Abelmoschus manihot</i> Seeds Restrain NLRP3 Inflammasome Assembly by Inhibiting ASC Oligomerization.PMC9301202Kang XLiu JTao YZhang YDiao QSu JLiu DYang FMeng XfalseChalcone Derivatives From <i>Abelmoschus manihot</i> Seeds Restrain NLRP3 Inflammasome Assembly by Inhibiting ASC Oligomerization.Three chalcone derivatives, abelmanihotols A-C <b>(1-3)</b>, and nine known compounds were isolated from <i>A. manihot</i> seeds, and their structures were determined using HRESIMS and NMR spectroscopic analysis. Compound <b>1</b> exhibited the most potent inhibitory effect (IC₅₀ = 4.79 ± 0.72 μM) against lipopolysaccharide (LPS)-induced NO release in THP-1 cells, and <b>s</b>ignificantly inhibited interleukin 1β (IL-1β) secretion, which is stimulated by LPS plus nigericin (IC₅₀ = 11.86 ± 1.20 μM), ATP or MSU, in THP-1 cells. A preliminary mechanism of action study indicated that compound <b>1</b> blocked the formation of nucleotide oligomerization domain-like receptor protein-3 (NLRP3) inflammasome formation by suppressing apoptosis-associated speck-like protein olig2022-01-01T00:00:00Z20222025-04-05T11:51:24.882Z2025-04-05T11:51:24.882ZS-EPMC93012023587358110.3389/fphar.2022.932198